惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

雷峰网
雷峰网
G
Google Developers Blog
D
Docker
The GitHub Blog
The GitHub Blog
H
Help Net Security
WordPress大学
WordPress大学
博客园_首页
Recent Announcements
Recent Announcements
P
Proofpoint News Feed
罗磊的独立博客
I
InfoQ
U
Unit 42
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
V
Visual Studio Blog
Jina AI
Jina AI
J
Java Code Geeks
博客园 - Franky
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
大猫的无限游戏
大猫的无限游戏
小众软件
小众软件
Last Week in AI
Last Week in AI
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
D
DataBreaches.Net
Google DeepMind News
Google DeepMind News

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings C...
2026-05-08 · via All Articles on Seeking Alpha

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call May 7, 2026 4:30 PM EDT

Company Participants

Vincent Anzalone - Head of Investor Relations & VP
Dr. Christopher Anzalone - Chairman, CEO & President
Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise
James Hamilton - Chief Medical Officer and Head of R&D
Daniel Apel - Chief Financial Officer

Conference Call Participants

Edward Tenthoff - Piper Sandler & Co., Research Division
Jason Gerberry - BofA Securities, Research Division
Ron Feiner - JPMorgan Chase & Co, Research Division
Avraham Novick - Morgan Stanley, Research Division
Maurice Raycroft - Jefferies LLC, Research Division
Joseph Thome - TD Cowen, Research Division
Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division
Amine Chaherli
Shelby Hill - RBC Capital Markets, Research Division
Jennifer Jia
Kaey Nakae - Chardan Capital Markets, LLC, Research Division

Presentation

Operator

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. [Operator Instructions]

I will now hand the conference call over to Vince Anzalone, Senior Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.

Vincent Anzalone
Head of Investor Relations & VP

Good afternoon, and thank you for joining us today to discuss Arrowhead's results for its fiscal 2026 second quarter ended March 31, 2026. With us today from management are President and CEO, Dr. Chris Anzalone, who will provide an overview; Andy Davis, Senior Vice President and Head of the Global Cardio Metabolic franchise, who will provide an update on commercialization activities; Dr. James Hamilton, Chief Medical Officer and Head of R&D, who will discuss our development programs; and Dan Apel, Chief Financial Officer, who will give an overview of the financials. Following management's prepared remarks, we will open the call to questions.

Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of